GlassScriptPhysician profile
Rajinder K Bhalla
NPI 1861454217
$2,465.82
in general payments reported to CMS, 2019-2025
22 companies · $29.49 in 2025
The $29.49 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $475 · 2021: $501 · 2022: $327 · 2023: $308 · 2024: $508 · 2025: $29.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $520 · Debt Forgiveness: $326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $519.52 |
| Debt Forgiveness | $325.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $353.60 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $330.84 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $327.83 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $215.82 | 2021-2023 | Verquvo |
| Esperion Therapeutics, INC. | $200.80 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.60 | 2019-2022 | |
| Boston Scientific Corporation | $150.62 | 2019-2025 | General - Brady |
| Biotronik INC. | $101.15 | 2019 | |
| Zoll Circulation INC | $98.31 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $84.16 | 2019-2023 | Camzyos |
| Abbott Laboratories | $76.71 | 2020 | |
| Amgen INC. | $74.95 | 2023-2024 | Repatha |
| Pfizer INC. | $50.81 | 2021-2023 | |
| Kowa Pharmaceuticals America, INC. | $50.49 | 2020-2021 | |
| Cvrx, INC. | $33.89 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $32.82 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $29.51 | 2019-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $28.31 | 2024 | Arcalyst |
| Avinger INC. | $20.92 | 2021 | |
| Scpharmaceuticals INC. | $19.19 | 2024 | |
| Novo Nordisk INC | $19.15 | 2024 | Rybelsus, Ozempic |
| Medtronic Minimed, INC. | $12.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajinder Bhalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.